Dr Reddy Share Price Jumps on Semaglutide Buzz — But Is Wall Street Buying It?

The news from Canada moved more quickly than most traders anticipated on the morning of April 23, 2026. According to reports, Dr. Reddy’s Laboratories was getting closer to receiving regulatory approval for a generic version of semaglutide, the popular diabetes and weight-loss drug that has subtly changed the pharmaceutical industry in recent years.

The stock increased by 6.3%. Desks that had been drowsy moments before came to life. Suddenly, analysts in both Mumbai and New York were retrieving old notes about the drugmaker based in Hyderabad.

Field	Details
Company Name	Dr. Reddy’s Laboratories Ltd.
Founder	Kallam Anji Reddy
Founded	1984
Headquarters	Hyderabad, India
U.S. Headquarters	East Brunswick, New Jersey
Listed On	NYSE: RDY, BSE, NSE
Market Capitalization	~$11.37 billion
Current P/E Ratio	17.63
50-Day Moving Average	$13.86
200-Day Moving Average	$13.88
Beta	0.35
Debt-to-Equity	0.03
Quarterly Revenue (Q reported Jan 21)	$969.81 million
EPS (latest quarter)	$0.16
Net Margin	16.41%
Return on Equity	15.89%
GF Score™	90/100
Consensus Analyst Rating	Hold
Consensus Price Target	$16.90
Sector	Healthcare — Drug Manufacturing
Key Markets	North America, India, Russia, Europe, Latin America

In a way, the story is familiar. These single-catalyst rallies, in which a regulatory hint from a foreign market propels a stock before anyone fully comprehends the fine print, frequently sweep up Indian pharmaceutical names. Preshant Nair of Citi, however, was not amused. He reaffirmed a sell, maintaining the company’s modest $50 million 2028 revenue projection for this specific medication while pointing out that at least five other players are already considering the same opportunity.

The discrepancy between what the sell-side is willing to underwrite and what the market appears to want to believe is difficult to ignore.

It seems like Dr. Reddy’s has always valued patience over zeal. The late Dr. Kallam Anji Reddy, a chemist who trained at the government-run Indian Drugs and Pharmaceuticals Limited before going it alone, founded the business in 1984. It expanded by starting with the less glamorous tasks. drugs in bulk. active components of pharmaceuticals. Western regulators hardly looked at exports to markets. It wasn’t until much later that it shifted to the challenging and costly game of obtaining FDA approvals and entering regulated territory.

By 2007, there were seven FDA-inspected facilities manufacturing APIs and seven more producing completed pharmaceuticals. The Biopharma Finished Dosage units in Hyderabad today have an industrial feel to them, unlike many Indian pharmaceutical campuses. The quality-control bays are lined with bins of rejected blister packs, the HVAC system hums, and the corridors are spotless.

For what they’re worth, the figures appear sound. Some value investors will interpret a P/E ratio of 17.63, which is close to the lower end of the company’s historical range, as a setup rather than a warning. A GF Score of 90 out of 100 indicates solid fundamentals in terms of growth, profitability, and financial strength.

For a business this size, the balance sheet is remarkably clean; a debt-to-equity ratio of 0.03 is the kind of number you typically see on a slide when management wants to brag. However, in the past 12 months, insiders have not purchased a share. Not one. which can mean something or nothing, depending on how you interpret it.

Money from institutions has been nibbling. In the fourth quarter, Rockefeller Capital Management strengthened its position. Russell Investments increased its ownership by over 800 percent. Then came smaller advisory firms. These trades aren’t particularly large, but they all follow the same pattern: a gradual, modest accumulation that occasionally precedes a re-rating and other times simply disappears into the background.

Semaglutide isn’t really what makes this moment intriguing. It’s that Dr. Reddy’s is once again being asked to demonstrate its ability to compete in a market where everyone has finally caught on. The bets that will matter in five years are the company’s research division in Atlanta, its push for biosimilars, and its covert expansion into dermatology and oncology.

There’s a sugar rush in the Canadian headline. The more difficult question is whether anyone can still be surprised by the methodical, patient culture that created this business. You get the impression that there won’t be a single press release with the solution as you watch it play out.